Psychedelics and Neural Plasticity: Therapeutic Implications

Overview

Journal J Neurosci

Specialty Neurology

Date 2022 Nov 9

PMID 36351821

Authors

Steven F Grieco

Eero Castren

Gitte M Knudsen

Alex C Kwan

David E Olson

Yi Zuo

Todd C Holmes

Xiangmin Xu

Affiliations

Soon will be listed here.

Abstract

Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural attitudes toward them are changing, and scientists are once again investigating the neural mechanisms through which these drugs impact brain function. The significance of this research direction is reflected by recent work, including work presented by these authors at the 2022 meeting of the Society for Neuroscience. As of 2022, there were hundreds of clinical trials recruiting participants for testing the therapeutic effects of psychedelics. Emerging evidence suggests that psychedelic drugs may exert some of their long-lasting therapeutic effects by inducing structural and functional neural plasticity. Herein, basic and clinical research attempting to elucidate the mechanisms of these compounds is showcased. Topics covered include psychedelic receptor binding sites, effects of psychedelics on gene expression, and on dendrites, and psychedelic effects on microcircuitry and brain-wide circuits. We describe unmet clinical needs and the current state of translation to the clinic for psychedelics, as well as other unanswered basic neuroscience questions addressable with future studies.

Citing Articles

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics.

Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D Psychedelic Med (New Rochelle). 2025; 1(2):74-86.

PMID: 40046726 PMC: 11658661. DOI: 10.1089/psymed.2023.0010.

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression.

Aboharb F, Davoudian P, Shao L, Liao C, Rzepka G, Wojtasiewicz C Nat Commun. 2025; 16(1):1590.

PMID: 39939591 PMC: 11822132. DOI: 10.1038/s41467-025-56850-6.

Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.

Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861191 PMC: 11769142. DOI: 10.3390/ph18010130.

Factors associated with cognitive flexibility in people with opioid-use disorder: a pilot study.

Regier P, Costa Macedo de Arruda T, Sinko L, Teitelman A, Childress A Front Psychiatry. 2025; 15():1505391.

PMID: 39748901 PMC: 11693614. DOI: 10.3389/fpsyt.2024.1505391.

Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.

Lima da Cruz R, Leao R, Moulin T Mol Med. 2024; 30(1):244.

PMID: 39701927 PMC: 11657683. DOI: 10.1186/s10020-024-01013-4.

References

Castren E . Neuronal network plasticity and recovery from depression. JAMA Psychiatry. 2013; 70(9):983-9. DOI: 10.1001/jamapsychiatry.2013.1. View

Aan Het Rot M, Zarate Jr C, Charney D, Mathew S . Ketamine for depression: where do we go from here?. Biol Psychiatry. 2012; 72(7):537-47. PMC: 3438349. DOI: 10.1016/j.biopsych.2012.05.003. View

Jones K, Srivastava D, Allen J, Strachan R, Roth B, Penzes P . Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A. 2009; 106(46):19575-80. PMC: 2780750. DOI: 10.1073/pnas.0905884106. View

Mei L, Xiong W . Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008; 9(6):437-52. PMC: 2682371. DOI: 10.1038/nrn2392. View

Olson D . Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci. 2018; 12:1179069518800508. PMC: 6149016. DOI: 10.1177/1179069518800508. View

Phoumthipphavong V, Barthas F, Hassett S, Kwan A . Longitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex. eNeuro. 2016; 3(2). PMC: 4819286. DOI: 10.1523/ENEURO.0133-15.2016. View

Nichols C, Garcia E, Sanders-Bush E . Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res Mol Brain Res. 2003; 111(1-2):182-8. DOI: 10.1016/s0169-328x(03)00029-9. View

Jakab R, Goldman-Rakic P . 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998; 95(2):735-40. PMC: 18490. DOI: 10.1073/pnas.95.2.735. View

Sampedro F, de la Fuente Revenga M, Valle M, Roberto N, Dominguez-Clave E, Elices M . Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. Int J Neuropsychopharmacol. 2017; 20(9):698-711. PMC: 5581489. DOI: 10.1093/ijnp/pyx036. View

10.

Griffiths R, Johnson M, Carducci M, Umbricht A, Richards W, Richards B . Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-1197. PMC: 5367557. DOI: 10.1177/0269881116675513. View

11.

Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

12.

Sawtell N, Frenkel M, Philpot B, Nakazawa K, Tonegawa S, Bear M . NMDA receptor-dependent ocular dominance plasticity in adult visual cortex. Neuron. 2003; 38(6):977-85. DOI: 10.1016/s0896-6273(03)00323-4. View

13.

Nichols D . Psychedelics. Pharmacol Rev. 2016; 68(2):264-355. PMC: 4813425. DOI: 10.1124/pr.115.011478. View

14.

McCulloch D, Korsbak Madsen M, Stenbaek D, Kristiansen S, Ozenne B, Jensen P . Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol. 2021; 36(1):74-84. PMC: 8801642. DOI: 10.1177/02698811211026454. View

15.

Barrett F, Doss M, Sepeda N, Pekar J, Griffiths R . Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020; 10(1):2214. PMC: 7010702. DOI: 10.1038/s41598-020-59282-y. View

16.

Miner L, Backstrom J, Sanders-Bush E, Sesack S . Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience. 2003; 116(1):107-17. DOI: 10.1016/s0306-4522(02)00580-8. View

17.

Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011; 218(4):649-65. PMC: 3308357. DOI: 10.1007/s00213-011-2358-5. View

18.

Hu H, Gan J, Jonas P . Interneurons. Fast-spiking, parvalbumin⁺ GABAergic interneurons: from cellular design to microcircuit function. Science. 2014; 345(6196):1255263. DOI: 10.1126/science.1255263. View

19.

Trajkovska V, Marcussen A, Vinberg M, Hartvig P, Aznar S, Knudsen G . Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull. 2007; 73(1-3):143-9. DOI: 10.1016/j.brainresbull.2007.03.009. View

20.

Doss M, Madden M, Gaddis A, Nebel M, Griffiths R, Mathur B . Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain. 2021; 145(2):441-456. PMC: 9014750. DOI: 10.1093/brain/awab406. View